BioSpace News Archive

Prominent Scientists and Clinical Investigators Bring Extensive Strategic Expertise in Targeted Oncology Across the Spectrum from Discovery and Translation to Development

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020 where management will participate in 1x1 meetings. A fireside chat held with Seres management will be made available on the News and Events section of the Company’s website on November 23, 2020. 3

Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data from a Phase I Dose Escalation Study of its lead candidate PT-112, an immunogenic cell death (ICD) inducer, in patients with relapsed or refractory multiple myeloma will be presented at the 62nd American So

Click Therapeutics announced today that Solera Health, the premier platform for addressing chronic conditions, will add Clickotine®, a clinically validated, fully digital smoking cessation program, for members of Blue Shield of California. Clicko

Pfizer, Inc. (NYSE: PFE) and LianBio announced today that they have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China. LianBio, founded by Perceptive Advisors, forged a collaboration with Pfizer to pursue an innovative business development opportunity. Both companies will be dedicated to advancing best-in-class therap

– OXLUMO is the First Therapeutic Approved for the Treatment of PH1, and the Only Therapy Proven to Lower Harmful Oxalate Levels that Drive the Progression of PH1 Disease –

Strategic Vaccines, LLC announced that Lockheed Martin will conduct a computational study of the Strategic Vaccines’ proprietary manufacturing systems designed to address emerging viral threats, beginning with COVID-19.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercor

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that new an

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced new clinical results from its Phase 1 study evaluating rivoceranib (apatinib)